Income Statement Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:52:40 2026-01-14 pm EST			5-day change	1st Jan Change
0.4230 ^USD	+1.22%		+6.40%	+3.80%

Jan. 13	Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities	RE
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI

49f47f028fa0c5.TYU6_YLW2q9EmBFb7njIs05liMnBPcmIlaOsWMt8IgI.P-FYvNudidUt6kBrmDunxnxW-5CSSq3d--f-KIhKVHsb2mLF1ZiSmgH6JQ

Published financial data: INTENSITY THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Selling General & Admin Expenses, Total	1.17M	2.16M	2.5M	3.53M	6.09M
R&D Expenses	5.05M	5.86M	5.13M	4.79M	10.5M
Other Operating Expenses, Total	6.22M	8.01M	7.63M	8.32M	16.58M
Operating Income	-6.22M	-8.01M	-7.63M	-8.32M	-16.58M
Interest Expense, Total	-	-	-	-305K	-
Interest And Investment Income	74.01K	2.61K	2.48K	324K	314K
Net Interest Expenses	74.01K	2.61K	2.48K	19K	314K
Other Non Operating Income (Expenses)	119K	116K	47.65K	24K	3K
EBT, Excl. Unusual Items	-6.03M	-7.9M	-7.58M	-8.28M	-16.27M
Other Unusual Items	-	-	-	-2.26M	-
EBT, Incl. Unusual Items	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Earnings From Continuing Operations	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Net Income to Company	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Net Income - (IS)	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Preferred Dividend and Other Adjustments	-	-	-	1.32M	-
Net Income to Common Incl Extra Items	-6.03M	-7.9M	-7.58M	-11.86M	-16.27M
Net Income to Common Excl. Extra Items	-6.03M	-7.9M	-7.58M	-11.86M	-16.27M
Per Share Items
Net EPS - Basic	-1.77	-2.32	-2.22	-1.38	-1.17
Basic EPS - Continuing Operations	-1.77	-2.32	-2.22	-1.38	-1.17
Basic Weighted Average Shares Outstanding	3.41M	3.41M	3.41M	8.62M	13.91M
Net EPS - Diluted	-1.77	-2.32	-2.22	-1.38	-1.17
Diluted EPS - Continuing Operations	-1.77	-2.32	-2.22	-1.38	-1.17
Diluted Weighted Average Shares Outstanding	3.41M	3.41M	3.41M	8.62M	13.91M
Normalized Basic EPS	-1.11	-1.45	-1.39	-0.6	-0.73
Normalized Diluted EPS	-1.11	-1.45	-1.39	-0.6	-0.73
Supplemental Items
EBITA	-6.22M	-8.01M	-7.63M	-8.32M	-16.58M
EBIT	-6.22M	-8.01M	-7.63M	-8.32M	-16.58M
Normalized Net Income	-3.77M	-4.93M	-4.74M	-5.17M	-10.17M
Supplemental Operating Expense Items
General and Administrative Expenses	1.17M	2.03M	2.38M	3.49M	6.09M
Research And Development Expense From Footnotes	5.05M	5.86M	5.13M	4.79M	10.5M
Net Rental Expense, Total	85.17K	129K	120K	40K	34K
Imputed Operating Lease Interest Expense	-	-	-	41.98K	-
Imputed Operating Lease Depreciation	-	-	-	-1.98K	-
Stock-Based Comp., R&D Exp. (Total)	439K	464K	803K	714K	1.24M
Stock-Based Comp., G&A Exp. (Total)	116K	256K	365K	684K	1.83M
Stock-Based Comp., Other (Total)	488	-	819	-	51K
Total Stock-Based Compensation	555K	720K	1.17M	1.4M	3.12M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	9.32M	4.54M	1.31M	8.56M	2.59M
Short Term Investments	-	-	-	6.22M	-
Total Cash And Short Term Investments	9.32M	4.54M	1.31M	14.78M	2.59M
Other Receivables	53.81K	51.26K	62.3K	-	-
Total Receivables	53.81K	51.26K	62.3K	-	-
Prepaid Expenses	67.17K	70.44K	29.36K	682K	773K
Other Current Assets, Total	191K	69.28K	46.8K	6K	-
Total Current Assets	9.63M	4.73M	1.45M	15.46M	3.36M
Net Property Plant And Equipment	490K	318K	139K	147K	122K
Other Long-Term Assets, Total	31.7K	168K	168K	1.68M	1.3M
Total Assets	10.15M	5.22M	1.76M	17.3M	4.78M
Liabilities
Accounts Payable, Total	223K	173K	603K	3.05M	1.22M
Accrued Expenses, Total	952K	335K	331K	452K	508K
Short-term Borrowings	-	2.02M	4.35M	-	-
Current Portion of Leases	171K	182K	143K	20K	28K
Other Current Liabilities	-	1.01M	1.39M	439K	-
Total Current Liabilities	1.35M	3.72M	6.82M	3.96M	1.76M
Long-Term Leases	326K	144K	-	138K	110K
Other Non Current Liabilities	36K	36K	36K	36K	-
Total Liabilities	1.71M	3.9M	6.85M	4.13M	1.86M
Preferred Stock Convertible	10M	10M	10M	-	-
Total Preferred Equity	10M	10M	10M	-	-
Common Stock, Total	682	682	341	1K	2K
Additional Paid In Capital	21.67M	22.39M	23.56M	63.68M	69.7M
Retained Earnings	-23.18M	-31.07M	-38.65M	-50.52M	-66.78M
Comprehensive Income and Other	-50K	-	-	-	-
Total Common Equity	-1.56M	-8.68M	-15.1M	13.16M	2.92M
Total Equity	8.44M	1.32M	-5.1M	13.16M	2.92M
Total Liabilities And Equity	10.15M	5.22M	1.76M	17.3M	4.78M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	3.41M	3.41M	3.41M	13.71M	15.18M
ECS Total Common Shares Outstanding	3.41M	3.41M	3.41M	13.71M	15.12M
Book Value / Share	-0.46	-2.55	-4.43	0.96	0.19
Tangible Book Value	-1.56M	-8.68M	-15.1M	13.16M	2.92M
Tangible Book Value Per Share	-0.46	-2.55	-4.43	0.96	0.19
Total Debt	497K	2.34M	4.49M	158K	138K
Net Debt	-8.82M	-2.2M	3.18M	-14.62M	-2.45M
Debt Equivalent Oper. Leases	681K	1.03M	961K	320K	272K
Account Code - Inventory Valuation	3	3	3	3	3
Full Time Employees	-	5	-	5	5
Part Time Employees	-	1	-	2	2

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-6.03M	-7.9M	-7.58M	-10.54M	-16.27M
Amortization of Deferred Charges, Total - (CF)	-	-	-	159K	-
Asset Writedown & Restructuring Costs	117K	172K	179K	147K	25K
Stock-Based Compensation (CF)	555K	720K	1.17M	1.4M	3.12M
Other Operating Activities, Total	-	-	-	2.26M	-
Change In Accounts Payable	-171K	-50.2K	431K	1.63M	-2.27M
Change in Other Net Operating Assets	159K	227K	326K	-2.26M	167K
Cash from Operations	-5.37M	-6.83M	-5.48M	-7.2M	-15.22M
Investment in Marketable and Equity Securities, Total	4.56M	-	-	-6.02M	6.35M
Cash from Investing	4.56M	-	-	-6.02M	6.35M
Short Term Debt Issued, Total	-	2M	2.25M	230K	-
Total Debt Issued	-	2M	2.25M	230K	-
Issuance of Common Stock	25K	50K	-	22.48M	3.55M
Issuance of Preferred Stock	6.27M	-	-	-	-
Other Financing Activities, Total	-	-	-	-2.23M	-653K
Cash from Financing	6.29M	2.05M	2.25M	20.47M	2.9M
Net Change in Cash	5.49M	-4.78M	-3.23M	7.24M	-5.97M
Supplemental Items
Levered Free Cash Flow	-3.23M	-3.97M	-2.74M	-2.77M	-9.54M
Unlevered Free Cash Flow	-3.23M	-3.97M	-2.74M	-2.74M	-9.54M
Change In Net Working Capital	-107K	-318K	-858K	-1.06M	2.3M
Net Debt Issued / Repaid	-	2M	2.25M	230K	-

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-40.77	-65.19	-136.81	-54.58	-93.9
Return on Total Capital	-46.24	-79.52	-312.46	-81.79	-126.6
Return On Equity %	-75.07	-161.84	401.02	-261.36	-202.34
Return on Common Equity	306.52	154.16	63.76	1.23K	-202.34
Short Term Liquidity
Current Ratio	7.15	1.27	0.21	3.91	1.92
Quick Ratio	6.96	1.23	0.2	3.73	1.48
Operating Cash Flow to Current Liabilities	-3.99	-1.83	-0.8	-1.82	-8.67
Long Term Solvency
Total Debt/Equity	5.89	178.03	-88.12	1.2	4.73
Total Debt / Total Capital	5.57	64.03	-741.93	1.19	4.52
LT Debt/Equity	3.86	10.91	-	1.05	3.77
Long-Term Debt / Total Capital	3.65	3.92	-	1.04	3.6
Total Liabilities / Total Assets	16.83	74.77	390.08	23.9	38.99
EBIT / Interest Expense	-	-	-	-27.28	-
EBITDA / Interest Expense	-	-	-	-27.14	-
(EBITDA - Capex) / Interest Expense	-	-	-	-27.14	-
Total Debt / EBITDA	-0.08	-0.3	-0.6	-0.02	-0.01
Net Debt / EBITDA	1.44	0.28	-0.42	1.77	0.15
Total Debt / (EBITDA - Capex)	-0.08	-0.3	-0.6	-0.02	-0.01
Net Debt / (EBITDA - Capex)	1.44	0.28	-0.42	1.77	0.15
Growth Over Prior Year
EBITA, 1 Yr. Growth %	9.65	28.77	-4.76	10.19	99.36
EBIT, 1 Yr. Growth %	9.65	28.77	-4.76	10.19	99.36
Earnings From Cont. Operations, 1 Yr. Growth %	12.09	30.93	-3.97	38.99	54.37
Net Income, 1 Yr. Growth %	12.09	30.93	-3.97	38.99	54.37
Normalized Net Income, 1 Yr. Growth %	12.09	30.93	-3.97	9.15	96.57
Diluted EPS Before Extra, 1 Yr. Growth %	11.88	30.91	-3.97	-38.08	-15.03
Net Property, Plant and Equip., 1 Yr. Growth %	94.03	-35.11	-56.28	5.76	-17.01
Total Assets, 1 Yr. Growth %	13.64	-48.61	-66.31	884.35	-72.34
Tangible Book Value, 1 Yr. Growth %	-34.41	457.18	73.85	-187.18	-77.83
Common Equity, 1 Yr. Growth %	-34.41	457.18	73.85	-187.18	-77.83
Cash From Operations, 1 Yr. Growth %	21.6	27.13	-19.77	31.55	111.24
Levered Free Cash Flow, 1 Yr. Growth %	-	29.07	-30.91	0.96	244.35
Unlevered Free Cash Flow, 1 Yr. Growth %	-	29.07	-30.91	1.71	248.33
Compound Annual Growth Rate Over Two Years
EBITA, 2 Yr. CAGR %	-	18.83	10.74	1.89	48.21
EBIT, 2 Yr. CAGR %	-	18.83	10.74	1.89	48.21
Earnings From Cont. Operations, 2 Yr. CAGR %	-	21.15	12.13	15.53	46.48
Net Income, 2 Yr. CAGR %	-	21.15	12.13	15.53	46.48
Normalized Net Income, 2 Yr. CAGR %	-	21.15	12.13	2.38	46.48
Diluted EPS Before Extra, 2 Yr. CAGR %	-	21.02	12.12	-22.89	-27.47
Net Property, Plant and Equip., 2 Yr. CAGR %	-	12.21	-46.74	-32.02	-6.31
Total Assets, 2 Yr. CAGR %	-	-23.58	-58.39	82.09	64.99
Tangible Book Value, 2 Yr. CAGR %	-	91.17	211.23	23.11	-56.04
Common Equity, 2 Yr. CAGR %	-	91.17	211.23	23.11	-56.04
Cash From Operations, 2 Yr. CAGR %	-	24.33	0.99	2.73	66.7
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-5.57	-16.48	86.46
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-5.57	-16.96	88.23
Compound Annual Growth Rate Over Three Years
EBITA, 3 Yr. CAGR %	-	-	10.38	10.16	27.44
EBIT, 3 Yr. CAGR %	-	-	10.38	10.16	27.44
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	12.12	20.45	27.25
Net Income, 3 Yr. CAGR %	-	-	12.12	20.45	27.25
Normalized Net Income, 3 Yr. CAGR %	-	-	12.12	11.13	27.25
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	12.04	-8.01	-20.35
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-18.04	-33.07	-27.35
Total Assets, 3 Yr. CAGR %	-	-	-41.84	19.44	-2.85
Tangible Book Value, 3 Yr. CAGR %	-	-	85.21	103.64	-30.48
Common Equity, 3 Yr. CAGR %	-	-	85.21	103.64	-30.48
Cash From Operations, 3 Yr. CAGR %	-	-	7.44	10.29	30.64
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	-3.44	33.93
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	-3.81	33.93
Compound Annual Growth Rate Over Five Years
EBITA, 5 Yr. CAGR %	-	-	-	-	23.92
EBIT, 5 Yr. CAGR %	-	-	-	-	23.92
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	24.77
Net Income, 5 Yr. CAGR %	-	-	-	-	24.77
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	24.77
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-	-5.85
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	-	-13.55
Total Assets, 5 Yr. CAGR %	-	-	-	-	-11.74
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	4.19
Common Equity, 5 Yr. CAGR %	-	-	-	-	4.19
Cash From Operations, 5 Yr. CAGR %	-	-	-	-	28.08